Catalent to Acquire Juniper, Adding Early Drug Development Capabilities

Catalent said today it has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that adds a U.K. center of excellence for early drug development to similar centers that the buyer established on the West Coast and plans to create on the East Coast.The acquisition continues the consolidation of contract development and manufacturing organizations (CDMOs) worldwide—a consolidation that included Catalent’s $950 million purchase of Cook Pharmica late last year. Juniper&rs